Mesiproc (Clopidogrel)

Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑induced activation of the glycoprotein IIb/IIIa complex. This inhibition stops platelets from aggregating, thereby reducing the formation of arterial clots.

The dosage of Mesiproc is determined by the prescribing clinician based on the individual patient's clinical condition, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for clopidogrel in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To request Mesiproc, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesiproc (clopidogrel) is a P2Y12 receptor antagonist, similar to ticagrelor and prasugrel. Unlike ticagrelor, clopidogrel requires metabolic activation and has a longer onset of action, while prasugrel may have a higher bleeding risk in certain populations. Choice of therapy depends on patient risk profile and physician judgment.

Mesiproc should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and out of reach of children.

Mesiproc is taken orally, usually as a whole tablet with or without food. Patients should swallow the tablet whole and avoid crushing or chewing it unless otherwise instructed by a healthcare professional.

The most serious risks include severe or uncontrolled bleeding, thrombotic thrombocytopenic purpura, and rare allergic reactions such as anaphylaxis. Patients should be educated to report any unusual bleeding, bruising, or signs of hypersensitivity promptly.

Mesiproc is contraindicated in patients with active pathological bleeding, known hypersensitivity to clopidogrel or any component of the formulation, and in individuals who have had a recent intracranial hemorrhage. Clinicians should also exercise caution in patients with severe hepatic impairment.